RetiSpec is a leading medical imaging company that utilizes advanced Artificial Intelligence (AI) to develop a revolutionary screening tool for early and accurate detection of Alzheimer's disease markers in the eye. By leveraging its proprietary technology, RetiSpec offers a non-invasive and more accessible solution for the early detection of Alzheimer's disease, surpassing the limitations of current assessment methods. Driven by a profound vision, RetiSpec aims to ensure a better future for Alzheimer's by enabling widespread and affordable detection of neurodegenerative disease markers through scalable retinal screening.

To achieve this, RetiSpec is developing explainable AI (XAI) for the early detection of Alzheimer's disease through a simple eye test. The team at RetiSpec comprises highly skilled professionals in various roles, including data scientists, software engineers, clinical operations managers, product specialists, and more. With an esteemed Board of Directors and collaborations with notable organizations, RetiSpec is at the forefront of advancing Alzheimer's research and detection.

Please note that RetiSpec's technology is currently for research use only, signaling their commitment to continuous improvement and innovation in the field